NCT02761174View on ClinicalTrials.gov

Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 13, 2016

Primary Completion Date

July 11, 2016

Study Completion Date

January 13, 2017

Conditions
Telangiectasias
Interventions
DRUG

Brimonidine

Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control

OTHER

IPL+air-cooling

IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling

Trial Locations (1)

2200

Bispebjerg Hospital, Copenhagen NV

All Listed Sponsors
collaborator

Skinperium, Christine Dierickx

UNKNOWN

collaborator

Ellipse A/S Agern Allé 11, 2970 Hørsholm

UNKNOWN

lead

Merete Haedersdal

OTHER

NCT02761174 - Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias | Biotech Hunter | Biotech Hunter